Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Competition between Drug Distributors Heats Up in Zhejiang Province

publication date: Mar 24, 2011
Sinopharm Group announced it will acquire Zhejiang Wenling Drug Materials, based in Taizhou, Zhejiang province. Wenling, whose yearly revenues have averaged 1.1 billion RMB ($168 million) over the past three years, generates 90% of its business by selling to hospitals. The acquisition amped up a competition in Zhejiang between Sinopharm and its chief drug rival in the drug distribution sector, Shanghai Pharmaceuticals Holding. More details....

Stock Symbols: (HK: 1099) (SHE: 601607)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital